Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Pablo Tebas, MD

Pablo Tebas, MD Physician

Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Director, Developmental Core, Penn Center for AIDS Research
Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Tebas is a Penn Medicine employed physician.

About Dr. Pablo Tebas

Recognized by Best Doctors in America 2007-2008, 2009-2010, 2011-2012

Clinical Specialties


  • Infectious Diseases

Programs & Centers:

Board Certification:

  • Infectious Disease, 2005
  • Internal Medicine, 2004

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Practice Locations and Appointments

  • Infectious Diseases

    Perelman Center for Advanced Medicine South Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Universidad Autonoma De Madrid
Fellowship: Barnes-Jewish Hospital - Washington University, St. Louis


American Society for Microbiology (ASM), National Department of Health and Human Services (DHHS), National HIV Medical Association (HIVMA-IDSA), National Infectious Diseases Society of America (IDSA), National International AIDS Society, International International AIDS Society-USA, National NIH, Division of AIDS, AIDS Clinical Trial Group, National Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (Spanish Society of Infectious Diseases and Clinical Microbiology), National Sociedad Española de Medicina Interna (Spanish Society of Internal Medicine), National

Hospital Affiliation

Dr. Tebas is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Selected Publications:

Jacobson, J. M., Zheng, L., Wilson, C. C., Tebas, P., Matining, R. M., Egan, M. A., Eldridge, J., Landay, A. L., Clifford, D. B., Luetkemeyer, A. F., Tiu, J., Martinez, A. L., Janik, J., Spitz, T. A., Hural, J., McElrath, J., Frahm, N., Actg A. Protocol Team: The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection J Acquir Immune Defic Syndr 71 (2): 163-71,2016.

Bedimo, R., Cutrell, J., Zhang, S., Drechsler, H., Gao, A., Brown, G., Farukhi, I., Castanon, R., Tebas, P., Maalouf, N. M.: Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease AIDS 30 (4): 601-8,2016.

Wohl, D., Oka, S., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas, J. R., Rashbaum, B., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax, P. E., Cheng, A., Zhong, L., Callebaut, C., Das, M., Fordyce, M., Gs-Us- Study Team: A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for initial HIV-1 Treatment: Week 96 results J Acquir Immune Defic Syndr : 2016.

Gowda, C., McKittrick, N., Kim, D., Kappes, R. A., Lo Re, V., 3rd, Tebas, P.: Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons AIDS Res Treat 2015 : 653840,2015.

Bedimo, R., Kang, M., Tebas, P., Overton, E. T., Hollabaugh, K., McComsey, G., Bhattacharya, D., Evans, C., Brown, T. T., Taiwo, B.: Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients AIDS Res Hum Retroviruses : 2015.

Tebas, P., Kumar, P., Hicks, C., Granier, C., Wynne, B., Min, S., Pappa, K.: Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks AIDS : 2015.

Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., Marks, K., Luetkemeyer, A., Baden, R. P., Sax, P. E., Gane, E., Santana-Bagur, J., Stamm, L. M., Yang, J. C., German, P., Dvory-Sobol, H., Ni, L., Pang, P. S., McHutchison, J. G., Stedman, C. A., Morales-Ramirez, J. O., Brau, N., Jayaweera, D., Colson, A. E., Tebas, P., Wong, D. K., Dieterich, D., Sulkowski, M., I. O. N. Investigators: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 N Engl J Med 373 (8): 705-13,2015.

Overton, E. T., Chan, E. S., Brown, T. T., Tebas, P., McComsey, G. A., Melbourne, K. M., Napoli, A., Hardin, W. R., Ribaudo, H. J., Yin, M. T.: Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial Ann Intern Med 162 (12): 815-24,2015.

Tebas, P., Spitsin, S., Barrett, J. S., Tuluc, F., Elci, O., Korelitz, J. J., Wagner, W., Winters, A., Kim, D., Catalano, R., Evans, D. L., Douglas, S. D.: Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults AIDS 29 (8): 931-9,2015.

Morrow, M. P., Tebas, P., Yan, J., Ramirez, L., Slager, A., Kraynyak, K., Diehl, M., Shah, D., Khan, A., Lee, J., Boyer, J., Kim, J. J., Sardesai, N. Y., Weiner, D. B., Bagarazzi, M. L.: Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals Mol Ther 23 (3): 591-601,2015.

Academic Contact Info

Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 349-8092
Fax: (215) 349-8011
Patient appointments: 800-789-PENN (7366)

Related Links